AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04704986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PVI using the PolarX Cryoballoon (Boston Scientific)
Description: Patients randomized to PolarX cryoballoon group will undergo PVI using the PolarX Cryoballoon (Boston Scientific).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring.
Study NCT06270160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth
Description: The investigators are collaborating with the WelTel non-profit agency for a supportive SMS intervention. The WelTel system will manage the SMS intervention on their structured mobile phone platform (all SMS interactions are logged). Weekly 2-way supportive messages will automatically be sent on the same weekday with WelTel software to Arm 2+3 participants. The peer navigator will ask Arm 2+3 participants to respond to the SMS within 48 hours to confirm their wellbeing and will follow-up with non-responders. The Arm 2+3 peer navigators and Research Coordinator will access the server every 24-48 hours to triage and respond to participants who express a problem or need.
Study NCT06270160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creating Futures Livelihoods program
Description: Creating Futures is a group intervention that aims to help young people build their livelihoods, and was designed for use with youth (18-24) in urban informal settlements in South Africa.
Study NCT06519396 — intervention group
Intervention type: DEVICE
Intervention: ultrasonography evaluation
Description: Ultrasonographic measurements of the Achilles tendon were taken using Samsung Sonoace X7 ultrasound system equipped with an 8-13MHz linear transducer. After assuming a prone position on the examination table, the patients placed their feet against the wall and flexed their ankles to ensure optimal contact between the probe and the tendon. Measurements were taken separately on the right and left sides for each patient. Initially, the probe was positioned perpendicular to the long axis of the tendon for an axial plane assessment, followed by measurements of thickness (anterior-posterior), width (medial-lateral), and area at the level of the medial malleolus. The thickness and width measurements utilized the tendon's major axes, while the area measurements were automatically calculated by the device through continuous tracing of the tendon circumference in the same section
Study NCT06519396 — intervention group
Intervention type: DEVICE
Intervention: tetrax device evaluation
Description: A Tetrax device was used to assess static balance. The patient was positioned on the platform and subjected to tests in eight different positions. For each position, a test measurement was made for a duration of 32 seconds, for a total of approximately 5 minutes. The normal eyes-open position was taken as the reference. The effects of vision on balance were observed in the eyes-closed position. Balance is dependent on the back of the heels and the lower vertebrae in this position. Conversely, in the eyes-closed position with the head tilted 30 degrees forward, there is a load on the upper vertebrae and neck. Following the measurements, the Tetrax software program was used to calculate the Fall Index and Stability Index
Study NCT06023927 — intervention group
Intervention type: OTHER
Intervention: Clinical observation, diagnostic testing
Description: Glaucoma evaluation including structural and functional diagnostic testing at baseline and 3 subsequent follow-up visits over a period of 9 months
Study NCT05509387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation and naming training
Description: Participants will receive mild stimulation or no stimulation along with naming training
Study NCT05509387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation and naming training
Description: Participants will receive mild stimulation or no stimulation along with naming training
Study NCT05509387 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation and naming training
Description: Participants will receive mild stimulation or no stimulation along with naming training
Study NCT06353906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel
Description: Induction: three cycles of intravenous carboplatin AUC5 (max 750 mg) and paclitaxel 175 mg/m2, during cycle 1, 2 and 3 (day 1, 22, 43)
Study NCT06353906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Induction: two cycles of intravenous pembrolizumab 400 mg during cycle 1 and 3 (day 1 and 43)~Adjuvant: up to seven cycles of fixed-dose intravenous pembrolizumab 400 mg, on day 1 every 6 weeks within 3-9 weeks after surgery
Study NCT06353906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial or total penectomy with inguinal and/or pelvic lymph node dissection
Description: Resection of part or all of the penis with complete removal of suspect lymphnodes in the inguinal and/or pelvic area
Study NCT06259331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-812 (600mg, QD)
Description: Viloxazine ER
Study NCT04703452 — intervention group
Intervention type: OTHER
Intervention: Indicators of central sensitisation
Description: Indicators of central sensitisation, assessed by the Central Sensitization Inventory
Study NCT06447844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsteoGen Plug
Description: OsteoGen® Plug is contoured to fill the three roots of the socket. Plug is delivered dry into a thoroughly debrided and actively bleeding socket. The OsteoGen® Plug is condensed firmly into the socket.
Study NCT06447844 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioGide
Description: BioGide is a resorbable collagen membrane
Study NCT05682131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Realgar Indigo naturalis formula
Description: Realgar Indigo naturalis formula was used in the induction, consolidation and intensive treatment of patients in intermediate or high risk
Study NCT05682131 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Conventional chemotherapy
Description: conventional chemotherapy
Study NCT05682131 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy
Description: conventional chemotherapy
Study NCT03634553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with e-health product
Description: The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
Study NCT03634553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: usual care, i.e. participates in regular training regime at the physiotherapy department
Study NCT04907032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 MG
Description: Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
Study NCT04907032 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Posterior Tibial Nerve Stimulation (PTNS)
Description: Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
Study NCT04907032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior Tibial Nerve Stimulation (PTNS)
Description: Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
Study NCT05281614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept is a fully humanized monoclonal antibody that targets TNFα.
Study NCT05281614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab is a humanized monoclonal antibody that targets α4ß7 integrin.
Study NCT05675553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot-assisted rehabilitation intelligent treatment
Description: Participants assigned to this condition were offered 10 individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, and explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants. The treatment framework is semi-structured through human-computer interaction. The forms of interaction include inquiries, statements, recommendations summaries, and knowledge assessments.
Study NCT05675553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment as usual
Description: Both groups will receive treatment as usual, including medication, exercise, and psychological education.
Study NCT05675553 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: treatment as usual
Description: Both groups will receive treatment as usual, including medication, exercise, and psychological education.
Study NCT05206474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRADYN
Description: One course of IRADYN® at baseline, consisting of a mono-dose intra-articular administration (2 ml).~From week 1 to week 6, injection will be performed, if necessary, during the visit, following the dosage reported in the instruction for use / summary of product characteristic.
Study NCT05415722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-501
Description: Investigational drug
Study NCT05415722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-101
Description: Investigational drug
Study NCT05415722 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT05741866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate impregnated bordered polyurethane dressing
Description: PIVCs will be dressed and secured at the participating sites~* RBWH and PUH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with non-sterile tape over extension tubing.~* QCH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference.
Study NCT05741866 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard bordered polyurethane dressing
Description: PIVCs will be dressed and secured as per standard practice at the participating sites~* RBWH and PUH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1683) and non-sterile tape strip over extension tubing.~* QCH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1682 or 1683) and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference.
Study NCT04789616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Half of the participants will take maraviroc for a period of 8 weeks.
Study NCT04789616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: All participants will take part in an 8-week exercise program. While in-hospital, participants will undergo standard of care rehabilitation (estimated at 45 minutes each daily for physiotherapy \& occupational therapy) plus a supplementary upper extremity exercise program (Graded Repetitive Arm Supplementary Program (GRASP); estimated at 1 hour daily).~After discharge from inpatient care, participants will complete an at-home supplementary upper and lower extremity exercise program. This program will include 30 minutes daily walking or sit-to-stand exercises and 30 minutes daily practice using the GRASP program.
Study NCT04789616 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Program
Description: All participants will take part in an 8-week exercise program. While in-hospital, participants will undergo standard of care rehabilitation (estimated at 45 minutes each daily for physiotherapy \& occupational therapy) plus a supplementary upper extremity exercise program (Graded Repetitive Arm Supplementary Program (GRASP); estimated at 1 hour daily).~After discharge from inpatient care, participants will complete an at-home supplementary upper and lower extremity exercise program. This program will include 30 minutes daily walking or sit-to-stand exercises and 30 minutes daily practice using the GRASP program.
Study NCT04789616 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of the participants will take a placebo for a period of 8 weeks.
Study NCT04789616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Sensor
Description: Participants will be asked to wear small activity sensors (one on each wrist and one on each ankle, total of four sensors) at the baseline, 4-week, 8-week, and 6-month assessments for 7 consecutive days. Activity related to walking, sleep, physical activity, and arm and leg movement throughout the day will be measured.~The sensors will be worn for a total of 28 days throughout the study.
Study NCT04817410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emergency Department Initiated Oral Naltrexone
Description: Emergency Department Initiated Oral Naltrexone
Study NCT04717986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: patients who meet the inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 12 months
Study NCT05473494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training group
Description: Trainings on diabetic foot care consisting of min 20 max 40 minutes will be given in 5 sessions for nine weeks. Training will be given face to face online.
Study NCT05473494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Group not to be trained.
Study NCT04789616 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Activity Sensor
Description: Participants will be asked to wear small activity sensors (one on each wrist and one on each ankle, total of four sensors) at the baseline, 4-week, 8-week, and 6-month assessments for 7 consecutive days. Activity related to walking, sleep, physical activity, and arm and leg movement throughout the day will be measured.~The sensors will be worn for a total of 28 days throughout the study.
Study NCT04789616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Learning
Description: Participants will be asked to perform a computer-based motor learning assessment at the baseline, 4-week, 8-week, and 6-month assessments. A retention task, which involves shorter versions of the initial tasks, will also be completed within 72 hours of the initial assessment (initial test and retention test).
Study NCT04789616 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motor Learning
Description: Participants will be asked to perform a computer-based motor learning assessment at the baseline, 4-week, 8-week, and 6-month assessments. A retention task, which involves shorter versions of the initial tasks, will also be completed within 72 hours of the initial assessment (initial test and retention test).
Study NCT05850286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-BCMA CAR-T
Description: Autologous BCMA-directed CAR-T cells, double infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
Study NCT05850286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRD-based Regimen
Description: Bortezomib, Lenalidomide and Dexamethasone
Study NCT04717986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months
Study NCT05954117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose tissue biopsies
Description: During the 2 surgical time, when patient is under general anesthesia, two adipose tissue biopsies of 20cc each (one from abdominal subcutaneous adipose tissue and one from omental adipose tissue) are taken and characterize by oxygraphy (respirometry).~Before the 2 surgical times (before and after chemotherapy) patients will have evaluation of the muscle strength, cachexia (by scan analysis), energy expenditure, anthropometric criteria and biochemical inflammatory.
Study NCT05033769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Injection [Halaven]
Description: on days 1 and 8 q21d
Study NCT05033769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Description: on days 1, 8, and 15 q21d
Study NCT05669612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy based protein
Description: Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
Study NCT05669612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed protein
Description: Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
Study NCT05669612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant-based protein 1
Description: Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
Study NCT05669612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant-based protein 2
Description: Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
Study NCT05050461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunological analyses
Description: Immunological analyses will be performed at inclusion in both arms
Study NCT05050461 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immunological analyses
Description: Immunological analyses will be performed at inclusion in both arms
Study NCT06221033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manual hyperinflation
Description: Each participant will assume a relaxed comfortable in supine position. Bag valve resuscitation circuit locked at pressure 35 cm H20 will be used. Six sets of six MHI breaths will be applied. MHI breaths had a slow inspiration for three seconds duration, a three second end inspiratory pause (hold) then an uninterrupted expiration as a quick release
Study NCT06221033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic proprioceptive neuromuscular facilitation technique
Description: Rhythmic initiation technique that is derived from the PNF concept will be initiated by four 20-second manual diaphragm stimulations. After every stimulation the patient rested for one minute. Therapist's hands will be placed below the rib cage, just below the costal arches and will support patient's exhalation phase by slight lengthening his diaphragm simultaneously in posterior-superior direction using a verbal cue exhale. At the same time, the patient will verbally be encouraged to take a deep breath
Study NCT06221033 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: traditional physiotherapy
Description: This group will receive the traditional medical treatment and chest physiotherapy only.
Study NCT05680922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LB2102
Description: DLL3 directed autologous Chimeric Antigen Receptor T-cells
Study NCT05674019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI exam
Description: Brain MRI Morphometric exam
Study NCT05674019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI exam
Description: Brain MRI Morphometric exam
Study NCT05275166 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Induction of alcohol craving
Description: Presentation of images that may induce craving for alcohol. Recording of brain activity
Study NCT05275166 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires related to alcohol, quality of life, anxiety and depression
Study NCT05839314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier granule
Description: Huaier granule, oral administration, 10g each time, 3 times a day, continuous medication for 24 weeks. After 24 weeks of treatment, the dosage should be adjusted according to efficacy.
Study NCT05839314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin-angiotensin-aldosterone system inhibitors (RASI)
Description: Run-in period: All the patients should be treated with RASI for at least 4 weeks, and stop using any medicine containing Huaier or similar ingredients for at least 2 weeks before enrollment. If the patient is receiving RASI, the RASI can be continued until the end of the study. RASI can be adjusted once a week until the maximum tolerable dose based on albuminuria and blood pressure. If the patient is not receiving RASI therapy, then RASI is recommended.~Treatment period: RASI therapy is continued throughout the trial. Check blood pressure twice daily: morning and evening.
Study NCT05839314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin-aldosterone system inhibitors (RASI)
Description: Run-in period: All the patients should be treated with RASI for at least 4 weeks, and stop using any medicine containing Huaier or similar ingredients for at least 2 weeks before enrollment. If the patient is receiving RASI, the RASI can be continued until the end of the study. RASI can be adjusted once a week until the maximum tolerable dose based on albuminuria and blood pressure. If the patient is not receiving RASI therapy, then RASI is recommended.~Treatment period: RASI therapy is continued throughout the trial. Check blood pressure twice daily: morning and evening.